BURNABY, BRITISH COLUMBIA--(Marketwire - Sept. 21, 2012) - LED Medical Diagnostics Inc. (TSV VENTURE:LMD) (LED Dental), today announced the amendment of its distribution agreement with Henry Schein, Inc. (NASDAQ:HSIC). The Company's VELscope Vx product will now be available directly through LED.

Said LED's founder and CEO, Peter Whitehead: "While we are grateful for the valuable assistance and exposure provided by Henry Schein during an important period of the VELscope Vx's business development, we believe that our marketing and distribution efforts will be more profitably conducted through a variety of channels. Besides potentially increasing the return on sales to LED, taking greater control of our distribution will give us the opportunity to fine-tune our marketing and distribution plans as we capitalize on the success of our domestic and international sales campaigns."

Henry Schein, Inc. will continue to support VELscope Vx by supplying existing customers with VELscope consumables, and by continuing to service the large group practice client base.

Going forward, LED Medical Diagnostics will continue to aggressively market the VELscope Vx, to increase and solidify its market share and dominance in the area of fluorescence-based detection of oral-disease.

About LED Medical Diagnostics Inc.

LED Medical Diagnostics Inc. was founded in 2003 and is headquartered in Burnaby, British Columbia, Canada. Its wholly-owned subsidiary, LED Dental Inc., is the manufacturer of the Velscope Vx Enhanced Oral Assessment System. Velscope Vx devices, the first to apply tissue fluorescence visualization technology to the oral cavity, are used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device in the world. To date, the VELscope has sold over 12,000 units, and been used to perform an estimated 20-million exams. For more information, call +1 (604) 434-4614, or visit [ www.velscope.com ].

About the VELscope Vx

The Velscope Vx is a powerful FDA-approved tool used to screen for oral cancer. It saves lives and decreases morbidity by helping clinicians detect early stage oral cancer, pre-cancer, and other abnormalities in the mouth such as viral, fungal and bacterial infections. For more corporate information please call +1 (604) 434-4614, or visit [ www.velscope.com ].

Safe Harbor Statement

LED Medical Diagnostics Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by the company) contains statements that are forward-looking, such as statements relating to anticipated future revenues of the company and success of current product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of the company. For a description of additional risks and uncertainties, please refer to the company's filings with the Securities and Exchange Commission.